Disrupting macrophage metabolism to reduce immunosuppression and enhance therapy in pancreatic cancer
Disrupting macrophage metabolism to reduce immunosuppression and enhance therapy in pancreatic cancer
批准号:
10264934
负责人:
Christopher J. Halbrook
金额:
$20.09万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-30 至 2023-08-31
关键词:
AblationAdvisory CommitteesAmino AcidsAnti-Inflammatory AgentsArginineAttenuatedAutomobile DrivingBioenergeticsBiological AssayCD8-Positive T-LymphocytesCellsCessation of lifeClinicalCoculture TechniquesCollaborationsConsumptionCoupledCuesCytotoxic T-LymphocytesDTR geneDataDevelopment PlansDiagnosisDiseaseFoundationsGeneticGoalsHumanImmuneImmune checkpoint inhibitorImmunocompetentImmunosuppressionImmunotherapyInfiltrationInflammatoryInterruptionInvestigationK-Series Research Career ProgramsLigandsMAP Kinase GeneMalignant NeoplasmsMalignant neoplasm of pancreasMediatingMentored Clinical Scientist Development Award (K08)MentorsMentorshipMetabolicMetabolic PathwayMetabolismMichiganModelingMusMyelogenousMyeloid CellsMyeloid-derived suppressor cellsNutrientOrganoidsOutcomePDL1 inhibitorsPancreatic Ductal AdenocarcinomaPathway interactionsPatientsPhysiologyPositioning AttributeProductionRefractoryResearchResearch ProposalsResourcesRoleRunningS-Phase FractionSchemeShapesSignal PathwaySignal TransductionSolid NeoplasmSurvival RateSystemT-Cell ActivationT-LymphocyteTestingTranslatingTumor-associated macrophagesUnited StatesUniversitiesWorkanticancer activityarginasebasecancer cellcareer developmentconditional knockouteffective therapyextracellulargenetic approachimmune checkpointimmune checkpoint blockadeimprovedin vivoinhibitor/antagonistinsightmacrophagemedical schoolsmetabolomicsmouse modelpancreatic ductal adenocarcinoma cellpancreatic neoplasmpre-clinicalprogrammed cell death ligand 1programsskillstumortumor microenvironmenttumor-immune system interactions
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Pancreatic ductal adenocarcinoma (PDA) has the worst five-year survival rate of any major cancer. The
lethality of PDA is largely due to a lack of effective treatment options. Several barriers in PDA treatment are
conferred by the presence of immunosuppressive myeloid cells, which are highly represented in these tumors.
This immune suppression, driven largely by myeloid cells, renders PDA refractory to immunotherapy which has
proven effective in other solid tumors. Consequently, the elimination or reprogramming of these myeloid cells
offers potential avenues to provide a much-needed breakthrough for the treatment of patients with PDA.
The working hypothesis of this proposal is that interruption of the metabolic mechanisms driving immune
suppression will sensitize pancreatic cancer to immunotherapy. This will be examined in three parts. First, core
metabolic pathways in myeloid cells programmed by PDA cells will be identified and the requirement of these
programs for functionality will be tested (Aim 1). Next, the metabolic mechanisms by which these myeloid cells
mediate immune suppression will be investigated using human and murine co-culture, organoid, and in vivo
systems (Aim 2). Finally, these interactions will be targeted in tumor models coupled with checkpoint inhibitors
to determine the translational value of these approaches (Aim 3).
The mentored phase of this career development award will be overseen by Drs. Costas Lyssiotis and Weiping
Zou at the University of Michigan Medical School. In addition, Drs. Gabriel Nunez, Marina Pasca di Magliano,
and Charles Burant will serve as a postdoctoral advisory committee. Together, the mentorship team has set forth
a career development plan focused on research, collaboration, grantsmanship, presentation, mentorship, and
the acquisition of management skills necessary to run an independent research program. This will be carried out
utilizing the exceptional resources available at the University of Michigan.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Disrupting macrophage metabolism to reduce immunosuppression and enhance therapy in pancreatic cancer
-
批准号:10245783
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2020
-
负责人:Christopher J. Halbrook
-
依托单位:
Disrupting macrophage metabolism to reduce immunosuppression and enhance therapy in pancreatic cancer
-
批准号:9977349
-
项目类别:
-
资助金额:$12.29万
-
财政年份:2020
-
负责人:Christopher J. Halbrook
-
依托单位:
Disrupting macrophage metabolism to reduce immunosuppression and enhance therapy in pancreatic cancer
-
批准号:10462649
-
项目类别:
-
资助金额:$24.64万
-
财政年份:2020
-
负责人:Christopher J. Halbrook
-
依托单位:
海外基金